Axsome Therapeutics' AUVELITY Approved by FDA for Agitation in Alzheimer's Disease
Summary
Axsome Therapeutics announced that the FDA approved AUVELITY for managing agitation linked to dementia caused by Alzheimer's disease. AUVELITY becomes the first oral non-antipsychotic therapy approved for this condition, acting through modulation of NMDA and sigma-1 receptors. The approval represents a significant milestone in treating one of the most challenging behavioral symptoms of Alzheimer's disease.
Why it matters
This approval addresses a major unmet need in Alzheimer's disease care, as agitation affects a significant proportion of patients and is a leading cause of caregiver burden and institutionalization. Until now, treatment has relied primarily on off-label antipsychotics with significant safety concerns. AUVELITY offers a new, targeted pharmacological approach that could improve quality of life for patients and caregivers while reducing reliance on antipsychotic medications.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial